-
March 16, 2022 Mind Cure Health Halts All Psychedelic Business ActivityThe company was pursuing several psychedelic business strategies, including synthesizing ibogaine for researchers.
-
March 15, 2022 Top 5 Most Influential Psychedelic StudiesWe unpack five of the most important psychedelic studies conducted in recent years as psychedelics...
-
February 21, 2022 How Long Until Psychedelic Stocks Payoff?Our resident Psychedelic Investor explores one of the biggest questions on minds of those investing...
-
January 25, 2022 How Rick Doblin Guides Someone Through a Bad Psychedelic TripDifficult trips could be a problem in areas where psychedelics have been decriminalized, which is...
-
January 21, 2022 Psychedelic Business Spotlight – January 21Catch up on some of the biggest psychedelic business developments that unfolded in the last...
-
January 19, 2022 Majority of Mental Health Patients Support Access to Psychedelics, Survey FindsAmericans continue to open their minds to ketamine, psilocybin, and MDMA treatment for depression, anxiety,...
-
January 4, 2022 Health Canada Grants Special Access to Restricted Drugs for Psychedelic TherapyNew amendment reverses a 2013 Health Canada policy that prevented "a letter of authorization for...
-
December 30, 2021 2021: A Year in Review for the Psychedelics BusinessOur resident Psychedelic Investor looks back at some of this growing industry's biggest moments and...
-
December 29, 2021 Texas Further Embraces Psychedelics with Launch of Center for Psychedelic Research and TherapyResearch will focus on how various psychedelics can be used under proper supervision and guidance...
-
December 28, 2021 Ketamine Rapidly Reduces Depression, According to ‘Most Comprehensive Review’ of Evidence — But Patient Experiences Suggest More ApplicationsPsychedelic Spotlight speaks to a Field Trip Health patient and a psychotherapist, whose experiences suggest...
